Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 29 March 2011
Vol. 4, Issue 166, p. pc6
[DOI: 10.1126/scisignal.2001941]


Science Signaling Podcast: 29 March 2011

Thomas G. Graeber1,2 and Annalisa M. VanHook3

1 Crump Institute for Molecular Imaging; Institute for Molecular Medicine; Jonsson Comprehensive Cancer Center; David Geffen School of Medicine, Department of Molecular and Medical Pharmacology, University of California, Los Angeles CA 90095, USA.
2 California NanoSystems Institute, University of California, Los Angeles CA 90095, USA.
3 Web Editor, Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA.

Abstract: This Podcast features a conversation with the senior author of a Research Article published in the March 29 issue of Science Signaling. Thomas Graeber discusses his group’s phosphoproteomic analysis of a leukemia cell line, which reveals a mechanism by which leukemia cells may become resistant to chemotherapeutic agents that target tyrosine kinases. They found that the sensitivity of leukemias driven by the Bcr-Abl fusion protein to tyrosine kinase inhibitors depends on the cells’ reliance on negative feedback mechanisms that limit the activity of the Src family of tyrosine kinases.

Citation: T. G. Graeber, A. M. VanHook, Science Signaling Podcast: 29 March 2011. Sci. Signal. 4, pc6 (2011).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882